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ABSTRACT The marine alkaloid, Lamellarin D (Lam-D), has shown potent cytotoxicity in numerous 
cancer cell lines, and was recently identified as a potent topoisomerase I inhibitor. A library of open 
lactone analogs of Lam-D was prepared from a methyl 5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate scaffold (1) by introducing various aryl groups through sequential and regioselective 
bromination, followed by Pd(0)-catalyzed Suzuki cross-coupling chemistry.  The compounds were 
obtained in a 24-44% overall yield, and tested in a panel of three human tumor cell lines, MDA-MB-
231 (breast), A-549 (lung), and HT-29 (colon), to evaluate their cytotoxic potential.  From these data 
the SAR study concluded that more than 75% of the open-chain Lam-D analogs tested showed 
cytotoxicity in a low micromolar GI50 range. 
Marine alkaloids, cytotoxic activity, heterocycles, cross-coupling reactions 
INTRODUCTION 
In the search for new bioactive, small chemical molecules for research in chemical biology and 
medicinal chemistry one must choose a starting point from the vast chemical space.1 In this respect, 
natural products may serve as biologically pre-validated leads,2,3 and indeed more than 60% of the 
recently marketed drugs have been isolated from natural products or synthetic compounds based on 
natural products.4 With the recent advances in natural products science, including the synthesis of 
complex libraries,2,3 biosynthesis,5 and isolation techniques,6,7 the field has a promising future.8 In 
particular, marine and microbial environments may serve as a source of new bioactive chemical 
compounds.9 
Here we used Lamellarin D (Lam-D, Figure 1), a potent cytotoxic agent against various tumor cells, 
as a lead.  This marine alkaloid was first isolated from the marine prosobranch mollusc Lamellaria sp. 
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in 1985 by Faulkner and coworkers.10 Since then a family of about 35 structurally related lamellarins 
has been isolated from natural sources, and several synthetic strategies have been devised for these 
natural products.11,12 Of the family of lamellarins, Lam-D is one of the most potent lead candidates for 
anticancer chemotherapy. There is substantial evidence that Lam-D is an inhibitor of topoisomerase I13 
and a potent pro-apoptotic agent.14 Recently, topoisomerase I binding studies have been elaborated 
further by comparing Lam-D and Camptothecin15 (Figure 1) bound to the DNA–topoisomerase I 
complex using molecular dynamics simulations.16 These also correlate nicely with structure–activity 
relationships (SAR) obtained with homologs of Lam-D with distinct OMe/OH substitution patterns on 
the pentacyclic framework.16,17 Hence, the 8-OH and 20-OH groups (see Figure 1) are crucial for 
cytotoxic activity and also for topoisomerase I inhibition.  
Moreover, the unsaturated C-5–C-6 motif of Lam-D, as compared to the saturated analog (Lam-501, 
Figure 1), is important for potency,13,18 a trend that was also observed with a range of derivatives of 
Lam-D and Lam-501, in which the free phenolic sites were acylated.18 Furthermore, the latter study 
afforded potent candidates for in vivo preclinical development of their anti-tumor activity. Interestingly, 
derivatization of the 8-OH and 20-OH groups with amino acids, thus preserving the hydrogen bonding 
capacity at these sites, affords potent compounds, while acylation with various carboxylic acids results 
in a considerable decrease in potency.18  
We recently reported preliminary biological results showing that simplified tricyclic analogs of Lam-
D lacking the lactone, such as Open Lam-501 (Figure 1), retain some cytotoxic activity.19 This finding 
encouraged us to perform SAR studies using scaffold 1 by incorporating various aryl groups in 
positions 1 and 2, including their oxidized homologs (Figure 1).20  
In addition to the initial achievements in the assembly of the pentacyclic lamellarin framework21-23 
and total synthesis of Lam-D,21 pentacyclic and more simple lamellarins have been synthesized using 
solid-phase synthesis,24-26 which should facilitate the preparation of compound libraries for biological 
evaluation. However, here we found it more rational to prepare our library using the methyl 5,6-
dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate scaffold 1 (Figure 1), and protocols developed for 
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modular total synthesis of Lam-D27 and tricyclic analogs.19 While this study was in progress, another 
highly efficient synthesis of Lam-D and related analogs was published.28  
 
RESULTS AND DISCUSSION 
Chemistry 
The synthesis of an open-chain lamellarin analogs library was performed in solution starting from the 
methyl pyrrole-2-carboxylate by transformation into scaffold 1.19, 27  The key steps in the process were 
the introduction of the aryl substituents on positions 1 and 2 of the scaffold using the boron derivatives 
4 and 5 as building blocks for the final structure.   Following the procedure described for the total 
synthesis of Lam-D,27 the synthetic strategy used consisted of the regioselective bromination of the 
scaffold followed by a Pd(0)-catalyzed Suzuki cross-coupling reaction, oxidation and subsequent 
deprotection of all the phenols present in each compound.  The isopropyl ether was used as protecting 
group for the phenols present in the final compounds and was maintained throughout the synthetic 
process.29  
Three alternative ways were used to introduce the aryl groups on scaffold 1, according the final 
structure of the lamellarin analogs (Scheme 1).  The monoaryl compounds 6 were prepared by 
regioselective bromination of scaffold 1 on position 1 to give the bromoderivative 2, which was used for 
Suzuki cross-coupling with the boronic acids 4.  Diarylderivatives 7 with the same substitution pattern 
in both aryl groups were obtained from the dibromo-scaffold 3 by simultaneous introduction of both 
aryl groups.  Finally, for the diarylated-compounds 9, with different substituents on the phenyl rings, we 
used two sequential regioselective bromination and cross-coupling reactions starting from scaffold 1 
with the monoaryl-scaffolds 6 and bromides 8 as synthetic intermediates.27 
An extensive range of aryl boronic derivatives 4 and 5 were used as building blocks (see Table 1 for the 
structures).  Building blocks 4 are commercially available30  whereas the ortho-substituted borolanes 5 
were obtained in good yields (52-81%) from the proper aryl bromide by Pd(0)-catalyzed cross-coupling 
borylation using the pinacolborane, as described in the supporting information .27,31 
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All the Suzuki cross-coupling reactions between bromides 2, 3 and 8 and building blocks 4 were 
performed in DMF using Pd(PPh3)4 and K2CO3 as catalyst and base, respectively, with good yields.  
The phenolic group on position 4’of 6c (R4= OH) was protected as isopropoxy-ether by reaction with 2-
bromopropane in basic conditions, thereby giving 6d.32   Generally, transformation of 6 into 8 was 
performed using N-bromosuccinimide (NBS) in tetrahydofuran (THF) with a careful control of the 
reaction time in order to obtain the desired mono- and regio-bromination, thereby avoiding the 
formation of complex mixtures.33  Regioselective bromination of electron-rich systems like 6h, 6l, and 
6n using the same reaction conditions was unsuccessful because halogenation on the electron-rich 
aromatic ring could not be avoided with these compounds.34  The Suzuki reaction conditions used to 
introduce the second aryl ring on 8 were basically the same as when the boron-derivatives 4 were used.  
However, with the more hindered borolanes 5, several modification were required such as the slow 
addition of three equivalent35 of 5 and the use of K3PO4 as base to afford yields between 81% and 
quantitative for the second cross-coupling (see experimental conditions).36  Compounds 9a-i were 
prepared by reaction of scaffolds 8 and the second building block 5, as indicated in Table 1 and in the 
experimental conditions. 
Optimization of oxidation was performed with the 2-thienylderivative 4n.  Several experiments using 
2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) in CHCl3 at reflux temperature,  MnO2 in refluxing 
toluene or pyridine,37 or Pd-C in toluene or decalin38 afforded only traces of 10n.  The best reaction 
conditions were attained using DDQ in CHCl3 as solvent in a sealed tube and with microwave (MW) 
irradiation.  The aromatization of dihydroisoquinolines 6, 7 and 9 to give the planar system of 
pyrrolo[2,1-a]isoquinoline present in compounds 10-12 was accomplished using the same protocol as 
described in the supporting information.39 The 1H-NMR was crucial for the control of the reaction 
because the dihydroisoquinolines 6-9 have a characteristic ABXY spin system for the four protons of 
C5H2 and C
6H2 while the isoquinolines 10-12 hold an AB system in the aromatic area for the two 
protons C5H and C6H,  the former being a significant signal.   
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Compounds 9f-i and 12f-i both with bulky substituents in ortho of the aryl rings, showed restricted 
rotation and two conformers were observed by 1H- and 13C-NMR.  1H-NMR experiments with 12f at 
variable temperature showed the collapse of the signals at 75 ºC (see Figure 2 in the Supporting 
Information).  As an example, the coalescence of double doublets at 6.29 and 6.32 ppm40 at 25 ºC were 
easily observed (part a in Figure 1 of the Supporting Information) as a broad doublet at 6.31 ppm in the 
experiment at 75 ºC (part c in Figure 1 of the Supporting Information) and the same occurred with the 
methoxy-group signals.   In the coalescence temperature, the signal of collapsed groups  broadened and 
decreased in intensity.  Figure 2 shows the minimized energy forms of the two rotamers of compound 
12f, calculated by semi-empirical method PM3.41  The elimination of the bulky protecting groups led to 
the evanescence of the above-mentioned restricted rotation in all the compounds.   
All the isopropoxy-protecting groups of dihydroisoquinolines 6, 7, and 9 and fully aromatic systems 
10-12 were removed using AlCl3 in CH2Cl2,
24-26,42  giving a good yield of valuable phenols 13-18.43,44  
Despite the advantage of working with the protected phenol groups, the synthesis was performed 
without this protection in 4, as demonstrated with the synthesis of 17c and 15a.  Lamellarin analogs 13-
18 were obtained as reddish oils or white solids and their structures were confirmed by 1H- and 13C-
NMR, using heteronuclear bi-dimensional correlations such as HSQC, HMBC, and also MS and 
HRMS. 
Biological results 
A panel of three human tumor cell lines was used to evaluate the cytotoxic potential of the Lam-D 
analogs: A-549 lung carcinoma NSCL, HT-29 colon carcinoma cells, and MDA-MB-231 breast 
adenocarcinoma. 
A conventional colorimetric assay was set up to estimate GI50 values, i.e. the drug concentration 
which causes 50% of cell growth inhibition after 72 hours of continuous exposure to the test molecule. 
Lam-D was included in the test for comparison purposes. The results obtained are shown in Table 2. 
More than 75% of the open-chain Lam-D analogs tested showed cytotoxicity in a low micromolar GI50 
range. Molecular simplification of Lam-D by removing the lactone ring from all the analogs and by 
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additional elimination of one aryl group in derivatives 13 and 16 produced a decrease in activity with 
respect to Lam-D.  However, interestingly these data provide crucial information about the importance 
of the full structure for the biological activity of the molecules in spite of their low solubility in the 
biological medium. In a general overview, oxidized derivatives showed greater activity than the 
corresponding reduced analogs.13  Derivatives with electron-withdrawing substituents, such as nitro-
groups (i.e. 14m and 17m) decreased activity, and this decrease was dramatic with the introduction of a 
OCF3 substituent such as in 14i and 17i. The substitution pattern given by electron donor groups, such 
as OiPr, NMe2, OMe and OH, was fundamental for activity.  Comparison of 6c and 6d shows the 
importance of the free p-phenol on the aryl on position 1 of the scaffold.  Although few O-protected 
phenol analogs, such as 6c, 7a, 7c, and 7f,  presented cytotoxic activity, an important gain in activity 
was displayed by the same compounds with free OH functions. This observation can probably be 
attributed to the additional capacity of these analogs to perform hydrogen bonds with the active sites, as 
described for Lam-D.13  Although in the present work it has not been demonstrated the binding of this 
analogs with the same DNA-topI complex, other factors that could increase the activity are the 
solubility or the membrane-crossing issues.  The donor effect of the methoxy-substituents may explain 
why 14g and 17g were quite active, even without the possibility of acting as hydrogen bond donors.  
Compounds 18a, 17c, 18e, 18d and Lam-D had identical substituents on the scaffold and on the aryl of 
position 1, and proven a gradation in activity potency with the increase on the substitution of the aryl on 
position 2 of scaffold, despite 18e inactivity, presumably due to a lack of planarity probably by sterical 
hindrance.  The simplified analog 17c maintained 63% of activity of Lam-D in HT29 cells and most of 
this behaviour remained in the C4”-OH (same position as C-20 in Lam-D) group, as shown by 18a. To 
our knowledge, the open lactone compound 18d may produce lactonization in a physiological 
environment. Therefore, 18d must be considered for further study as a possible pharmacodynamic 
improvement for the validated Lam-D lead. 
Conclusion 
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Here we performed a SAR study using the marine alkaloid Lam-D. Efficient and convergent modular 
synthetic protocols were applied in the “diverted total” synthesis of more than 40 analogs of the natural 
product. This strategy allowed the introduction of structural elements that have not been studied 
previously in the lamellarin series. Thus, the SAR information provided in this study expands our 
knowledge about these compounds beyond substitutions on the core structure, which has already been 
provided by other groups.   
Overall, our results are consistent with previous findings, such as the critical importance for cytotoxic 
activity of the planarity of the tricyclic isoquinoline motif.  In addition, compounds with OH hydrogen 
bond donors at C-8 and C-4” were generally more potent than other analogs. Not surprisingly, 
compound 18d, which showed most resemblance to Lam-D, was the most potent compound against the 
three cell lines tested. This observation may be due to partial lactonization to give Lam-D under the 
assay conditions.  
However, remarkable retention of activity was observed for monoaryl analogs 13c and 16c against HT-
29 colon carcinoma cells, toward which these compounds were only ca. 5-fold less potent than Lam-D. 
Furthermore, the moderate activity of compound 17n against the A-549 and MDA-MB-231 cell lines 
(low micromolar) indicates that heterocyclic motifs may be included in a second-generation library. 
However, the hydrogen bond donor at C-20 should be preserved in future library designs.   On the basis 
of this work it is clear the importance of an extensive bioprospection of the natural sources to find lead 
candidates more than constructing ponderous libraries. 
Experimental Section  
A) General Procedures for Cross-Coupling Reactions.  Synthesis of Monoaryl-derivatives 6  A 
solution of bromide 2 (1.0 mmol) in DMF (20 mL) was purged with Ar and 4 (3.0 mmol), Pd(PPh3)4 
(0.1 mmol), and 2M K2CO3 (3.0 mmol) were added. The reaction mixture was stirred at 125 ºC and 
followed by TLC until absence of starting material. The solvent was removed after cooling to room 
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temperature and the residue was dissolved in EtOAc. The organic solution was washed with water and 
brine, dried and concentrated to give a crude material, which was later purified by column 
chromatography on silica gel. Elution with hexane/EtOAc (90:10 to 75:25) gave 6 (yield 32-92%).  
B) General Procedures for Cross-Coupling Reactions.  Synthesis of Diaryl-derivatives 7 A solution 
of 1,2-dibromide 3 (189 mg, 0.4 mmol) in DMF (8 mL) was purged with Ar for 10 min and 4 (2.4 
mmol), Pd(PPh3)4 (46 mg, 0.04 mmol), and 2M K2CO3 (2.4 mmol) were added.  The reaction mixture 
was stirred at 125 ºC and was then subjected to HPLC until disappearance of starting material or a 
maximum 20 h. The solvent was removed after cooling to room temperature and the residue was 
dissolved in EtOAc. The organic solution was washed with water and brine, dried and concentrated to 
give a crude material, which was later purified by column chromatography on silica gel. Elution with 
hexane/EtOAc (75:25 to 40:60) gave 7 (yield 34-87%). 
C) General Procedure for Regioselective Bromination of 6.  NBS (1.20 mmol) was added in one 
portion to a solution of 6 (1.00 mmol) in THF (13 mL). The mixture was stirred at 70 ºC under Ar for 
90 min. The solvent was removed and the residue was purified by flash chromatography. Elution with 
hexane/AcOEt (90:10 to 70:30) gave 8 (yield  84%- quantitative). 
D) General Procedures for Cross-Coupling Reactions.  Synthesis of Diaryl-derivatives 9a-c 
Arylboronic acids 4 (3.0 mmol), Pd(PPh3)4 (0.1 mmol), and 2M K2CO3 (3.0 mmol) were added to a 
purged solution of bromide 8 (1.0 mmol) in DMF (20 mL). The reaction mixture was stirred at 125 ºC 
for the time indicated for each compound (see Supporting Information). The solvent was removed and 
the residue was dissolved in EtOAc. The organic solution was washed with water and brine, dried and 
concentrated to give a crude material, which was later purified by column chromatography on silica gel. 
Elution with hexane/EtOAc (75:25 to 40:60) gave 9a-c (yield  71-89%). 
E) General Procedures for Cross-Coupling Reactions.  Synthesis of diaryl-derivatives  9d-i. A 
solution of bromide 8 (1.0 eq) in DMF (20 mL) was purged with Ar for 10 min and pinacol 
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phenylboronate 5 (1.0 mmol), Pd(PPh3)4 (10%), and 2M K3PO4 (3.0 mmol) were added. The reaction 
mixture was stirred at 115 ºC and another portion of boronate (2.0 mmol) was added drop-wise using a 
syringe pump during the first hour of reaction. The solvent was removed and the residue was dissolved 
in EtOAc. The organic solution was washed with water and brine, dried and concentrated to give a 
crude material, which was later purified by column chromatography on silica gel. Elution with 
hexane/EtOAc (75:25 to 60:40) gave 9d-i (yield  81%-quant). 
F) General Procedure for Oxidation. Synthesis of  compounds 10- 12.  A mixture of 6, 7 or 9 (1.0 
mmol) and DDQ (1.3 mmol) in dry CHCl3 (15 mL) was purged with Ar in a sealed vessel and 
microwaved at 120 ºC for 10 min. The organic solution was washed with 2M NaOH, water, and brine 
and then dried (MgSO4), filtered and evaporated in vacuum. Washing with NaOH was avoided for 
products with free phenolic groups. Purification by column chromatography on silica gel eluting with 
hexane/AcOEt (85:15 to 60:40) gave 10-12 (yield  48-95%). 
G) General Method for Deprotection. Preparation of compounds 13-18.  Anhydrous AlCl3 (1.3 
mmol) for each isopropoxy ether was added to a solution of compound 6, 7, or 9-12 (1 mmol) in dry 
CH2Cl2 (1 mL).  The mixture was sonicated for 10 min, quenched with sat. NH4Cl, then washed with 
water, and with brine. The aqueous solution was extracted with AcOEt. The organic extracts were dried 
and evaporated. The crude was purified by flash chromatography to give the entitled compounds (yield  
30-96%). 
Methyl 8-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-methoxy-5,6-dihydropyrrolo[2,1-a] 
isoquinoline-3-carboxylate (13c).  Following the general procedure G and starting from 6c (48 mg, 
0.11 mmol), elution with hexane/ AcOEt (80:20 to 70:30) gave a white solid (19 mg, 44%). M. p. 
(MeCN)  205-207 ºC.  IR (film) ν 3424, 1696, 1439, 1246 cm-1.1H NMR (CDCl3, 400 MHz) δ  2.98 (t, J 
= 6.4 Hz, 2H, H6); 3.47 (s, 3H, OMe); 3.84 (s, 3H, OMe); 3.86 (s, 3H, OMe); 4.59 (t, J = 6.4 Hz, 2H, 
H5); 5.62 (s, 1H, OH); 5.63 (s, 1H, OH); 6.78 (s, 1H); 6.85 (s, 1H); 6.91-6.97 (m, 4H).  13C NMR 
(CDCl3, 100 MHz) δ  28.9 (t); 42.5 (t); 51.1 (q); 55.6 (q); 56.0 (q); 108.1 (d); 112.0 (d); 113.8 (d); 114.3 
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(d); 119.1 (d); 120.0 (s); 120.5 (s); 121.5 (s); 122.4 (d); 126.8 (s); 128.6 (s); 131.7 (s); 144.5 (s); 144.9 
(s); 145.0 (s); 146.4 (s); 161.7 (s). MS (MALDI-TOF) m/z 395 (M, 100); 396 (M+1, 26).  HRMS m/z 
calcd. for C22H21NO6  395.1369, found 395.1366.  
Methyl 1-(2,5-dimethoxyphenyl)-8-hydroxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate (13e). Following the general procedure G and starting from 6e (17 mg, 0.04 mmol), elution 
with hexane/ AcOEt (80:20 to 70:30) gave a white solid (12 mg, 76%). M. p. (MeCN) 96-100 ºC.  IR 
(film) ν 3417, 1697, 1244 cm-1.  1H NMR (CDCl3, 400 MHz) δ  2.99 (t, J = 6.8 Hz, 2H, H6); 3.42 (s, 
3H, OMe); 3.65 (s, 3H, OMe); 3.75 (s, 3H, OMe); 3.83 (s, 3H, OMe); 4.62 (t, J = 6.8 Hz, 2H, H5); 5.55 
(s, 1H, OH); 6.67 (s, 1H); 6.75 (s, 1H); 6.85 (dd, J = 8.7, 2.8 Hz, 1H, H4’); 6.89 (d, J = 8.7 Hz, 1H, 
H3’); 6.90 (d, J = 2.8 Hz, 1H, H6’); 7.02 (s, 1H).  13C NMR (CDCl3, 100 MHz) δ  28.7 (t); 42.5 (t); 51.0 
(q); 55.4 (q); 55.8 (q); 56.2 (q); 107.7 (d); 112.1 (d); 113.5 (d); 113.6 (d); 116.7 (s); 117.4 (d); 119.9 (d); 
120.1 (s); 121.0 (s); 126.3 (s); 126.5 (s); 132.7 (s); 144.8 (s); 145.0 (s); 151.6 (s); 153.6 (s); 161.8 (s). 
MS (MALDI-TOF) m/z 409 (M, 100); 410 (M+1, 43).  ; MS (ESI-TOF) m/z 410 (M+1, 100). HRMS 
m/z calcd. for C23H24NO6 410.1598, found 410.1598. 
Methyl 1-(4-dimethylaminophenyl)-8-hydroxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3-carboxylate (13l). Following the general procedure G and starting from 6l (31 mg, 0.07 mmol), 
elution with hexane/ AcOEt (80:20 to 70:30) gave a white solid (25 mg, 90%).  M. p. (MeCN) 169-170 
ºC.  IR (film) ν 3441, 2925, 1693, 1439, 1194 cm-1.  1H NMR (CDCl3, 400 MHz) δ  2.95-2.96 (m, 8H, 
H6, NMe2); 3.47 (s, 3H, OMe); 3.83 (s, 3H, OMe); 4.57 (t, J = 6.4 Hz, 2H, H5); 5.58 (bs, 1H, OH); 6.76 
(s, 1H); 6.77 (d, J = 8.8 Hz, 2H); 6.90 (s, 1H); 6.95 (s, 1H); 7.31 (d, J = 8.8 Hz, 2H).  13C NMR (CDCl3, 
100 MHz) δ  28.9 (t); 40.8 (q); 42.5 (t); 51.0 (q); 55.6 (q); 108.2 (d); 112.8 (2d); 113.7 (d); 119.2 (d); 
119.9 (s); 120.9 (s); 121.7 (s); 124.7 (s); 126.7 (s); 130.1 (2d); 131.7 (s); 144.8 (s); 144.9 (s); 149.6 (s); 
161.8 (s). MS (MALDI-TOF) m/z 392 (M, 100).  MS (ESI-TOF) m/z 393 (M+1, 100). HRMS m/z calcd. 
for C23H25N2O4 393.1809, found 393.1809. 
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Methyl 1,2-bis(3,5-dimethoxy-4-hydroxyphenyl)-8-hydroxy-9-methoxy-5,6-dihydropyrrolo[2,1-
a]isoquinoline-3-carboxylate (14a, R4 = OH). Following the general procedure G and starting from 7a 
(24 mg, 0.04 mmol) and an excess of AlCl3 (0.8 mmol), on elution with hexane/ AcOEt (60:40 to 40:60) 
a yellowish solid (12 mg, 58%) was obtained. M. p. (MeCN) 118-120 ºC.  IR (film) 
ν 3430, 1689, 1437, 1210 cm-1.  1H NMR (CDCl3, 400 MHz) δ  3.02 (t, J = 6.4 Hz, 2H, H6); 3.40 (s, 
3H, OMe); 3.64 (s, 3H, OMe); 3.68 (s, 6H, 2OMe); 3.71 (s, 6H, 2OMe); 4.59 (t, J = 6.4 Hz, 2H, H5); 
5.41 (bs, 1H, OH); 5.43 (bs, 1H, OH); 5.58 (bs, 1H, OH); 6.39 (s, 2H); 6.40 (s, 2H); 6.67 (s, 1H); 6.78 
(s, 1H).  13C NMR (CDCl3, 100 MHz) δ 28.9 (t); 42.9 (t);  50.9 (q); 55.5 (q); 56.2 (2q); 56.4 (2q); 107.8 
(2d); 107.9 (2d); 108.3 (d); 113.7 (d); 117.8 (s); 120.2 (s); 121.4 (s); 126.3 (s); 126.5 (s); 126.9 (s); 
131.2 (s); 132.7 (s); 133.3 (s); 133.5 (s); 144.9 (s); 146.0 (2s); 146.9 (2s); 162.4 (s). MS (MALDI-TOF) 
m/z 577 (M, 100); 578 (M+1, 40). HRMS m/z calcd. for C31H31NO10  577.1948, found 577.1942. 
Methyl 8-hydroxy-1,2-bis(4-hydroxy-3-methoxyphenyl)-9-methoxy-5,6-dihydropyrrolo[2,1-
a]isoquinoline-3-carboxylate (14c).  Following the general procedure G and starting from 7c (28 mg, 
0.05 mmol), elution with hexane/ AcOEt (50:50 to AcOEt) gave a yellowish solid (15 mg, 60%).  M. p. 
(MeCN)  237-239 ºC.  IR (film) ν 3423, 1688, 1438, 1235, 1199 cm-1.1H NMR (CDCl3, 400 MHz) δ  
3.01 (t, J = 6.4 Hz, 2H, H6); 3.38 (s, 3H, OMe); 3.62 (s, 3H, OMe); 3.63 (s, 3H, OMe); 3.65 (s, 3H, 
OMe); 4.59 (t, J = 6.4 Hz, 2H, H5); 5.50 (bs, 1H, OH); 5.53 (bs, 1H, OH); 5.59 (bs, 1H, OH); 6.55 and 
6.58 (2d, J = 1.6 Hz, 2H, H2’, H2”); 6.63 (s, 1H); 6.70 and 6.75 (2dd, J = 8.4, 1.6 Hz, 2H, H6’, H6”); 
6.77 (s,1H); 6.78 and 6.83 (2d, J = 8.4 Hz, 2H, H5’, H5”).  13C NMR (CDCl3, 100 MHz): δ  28.9 (t); 
42.9 (t); 50.8 (q); 55.4 (q); 55.8 (q); 55.9 (q); 108.2 (d); 113.3 (d); 113.5 (d); 113.6 (d); 113.9 (d); 114.1 
(d); 117.8 (s); 120.4 (s); 121.4 (s); 123.9 (d); 124.3 (d); 126.9 (s); 127.3 (s); 127.5 (s); 131.3 (s); 132.7 
(s); 144.0 (s); 144.3 (s); 144.9 (s); 145.4 (2s); 146.3 (s); 162.5 (s). MS (MALDI-TOF) 517 (M, 100); 
518 (M+1, 15). HRMS m/z calcd. for C29H27NO8 517.1737, found 517.1731. 
Methyl 1,2-bis(3,4-dimethoxyphenyl)-8-hydroxy-9-methoxy-5,6-dihydropyrrolo[2,1-
a]isoquinoline-3-carboxylate (14f). Following the general procedure G and starting from 7f (92.0 mg, 
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0.16 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave 14f as a reddish oil (50.9 mg, 60%).  IR 
(film) ν 3410, 1691, 1437, 1254 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.01 (t, J = 6.5 Hz, 2H, H6); 3.36 
(s, 3H, OMe); 3.62 (s, 3H, OMe); 3.63 (s, 3H, CO2Me); 3.67 (s, 3H, OMe); 3.83 (s, 3H, OMe); 3.84 (s, 
3H, OMe); 4.59 (t, J = 6.5 Hz, 2H, H5); 5.67 (bs, 1H, OH); 6.62 (d, J = 1.6 Hz, 1H); 6.64 (d, J = 1.6 Hz, 
1H); 6.66 (s, 1H); 6.71 (dd, J = 8.4 and 1.6 Hz, 1H); 6.72 (s  1H); 6.74 (dd, J = 8.4 and 1.6 Hz,  1H); 
6.76 (d, J = 8.4 Hz, 1H); 6.77 (d, J = 8.4 Hz,  1H).  13C NMR (CDCl3, 100 MHz): δ 28.8 (t); 42.8 (t); 
50.8 (q); 55.3 (q); 55.5 (q); 55.6 (q); 55.7 (q); 55.8 (q); 108.2 (d); 109.9 (d); 110.9 (d); 113.7 (d); 114.1 
(d); 114.3 (d); 117.7 (s); 120.2 (s); 122.9 (d); 123.4 (d); 123.4 (s); 126.8 (s); 127.8 (s); 128.0 (s); 131.2 
(s); 132.5 (s); 141.6 (s); 144.8 (s); 147.3 (s); 147.5 (s); 147.5 (s); 148.5 (s); 162.3 (s).  MS (MALDI-
TOF) m/z 545 (M, 100).  HRMS m/z calcd. for C31H31NO8  545.2050, found 545.2044. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(4-methoxyphenyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate (14g).  Following the general procedure G and starting from 7g (18.2 mg, 0.034 mmol), 
elution with hexane/ AcOEt (80:20 to 50:50) gave 14g (6.8 mg, 41%) as a reddish oil.  IR (film) 
ν 2931, 1697 cm-1.  1H NMR (CDCl3, 400 MHz) δ  3.01 (t, J = 6.5 Hz, 2H, H6); 3.34 (s, 3H, OMe); 
3.59 (s, 3H, CO2Me); 3.76 (s, 3H, OMe); 3.77 (s, 3H, OMe); 4.59 (t, J = 6.5 Hz, 2H, H5); 5.52 (bs, 1H, 
OH); 6.50 (s, 1H); 6.74 (d, J = 9.0 Hz, 2H); 6.76 (s, 1H); 6.79 (d, J = 8.6 Hz, 2H); 7.03 (d, J = 9.0 Hz, 
2H); 7.06 (d, J = 8.6 Hz, 2H).  13C NMR (CDCl3, 100 MHz) δ 28.9 (t); 42.9 (t); 50.7 (q); 55.0 (q); 55.2 
(q); 55.2 (q); 108.2 (d); 109.7 (d); 112.5 (2d); 113.6 (2d); 117.9 (s); 120.5 (s); 121.2 (s); 126.8 (s); 127.6 
(s); 127.8 (s); 131.4 (s); 131.6 (2d); 132.3 (2d); 132.6 (s); 144.7 (s); 144.8 (s); 157.9 (s); 158.2 (s); 162.5 
(s).  MS (MALDI-TOF) m/z 485 (M). HRMS m/z calcd. for C29H27NO6 485.1838, found 485.1833. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(4-trifluoromethoxyphenyl)-5,6-dihydropyrrolo[2,1-
a]isoquinoline-3-carboxylate (14i).  Following the general procedure G and starting from 7i (25.9 mg, 
0.041 mmol), elution with hexane/ AcOEt (85:15 to 65:35) gave 14i (18.0 mg, 75%) as a reddish oil. IR 
(film) ν 2927, 1699 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.02 (t, J = 6.4 Hz, 2H, H6); 3.31 (s, 3H, 
OMe); 3.58 (s, 3H, CO2Me); 4.61 (t, J = 6.4 Hz, 2H, H5); 5.57 (bs, 1H, OH); 6.33 (s, 1H); 6.79 (s, 1H); 
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7.04-7.06 (m, 2H); 7.10-7.17 (m, 6H).  13C NMR (CDCl3, 100 MHz) δ 28.8 (t); 42.9 (t); 50.8 (q); 54.9 
(q); 107.9 (d); 113.8 (d); 118.2 (s); 119.5 (2d); 119.7 (q);  119.9 (q); 121.0 (s); 121.1 (2d); 121.7 (s); 
127.0 (s); 131.3 (s); 131.6 (s);  131.8 (2d); 132.6 (2d); 133.8 (s); 134.3 (s), 144.9 (s); 145.1 (s); 147.8 
(s); 147.9 (s); 161.9 (s).   MS (MALDI-TOF) m/z 593 (M); 594 (M+1).  HRMS m/z calcd. for 
C29H21F6NO6  593.1273, found 593.1268 
Methyl 8-hydroxy-1,2-bis(4-hydroxyphenyl)-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate (14j).  Following the general procedure G and starting from 7j (28.6 mg, 0.049 mmol), 
elution with hexane/ AcOEt (60:40 to AcOEt) gave 14j (15.0 mg, 67%) as a pale solid. M. p. (MeCN) 
190-5 ºC.  IR (film) ν 3194, 1683, 1436, 1267 cm-1.  1H NMR (DMSO-d6, 400 MHz) δ 2.92 (m, 2H, 
H6); 3.21 (s, 3H, OMe); 3.48 (s, 3H, CO2Me); 4.43 (m, 2H, H5); 6.39 (s, 1H); 6.55 (d, J = 8.1 Hz, 2H); 
6.67 (m, 3H); 6.85 (d, J = 8.2 Hz, 2H); 6.88 (d, J = 8.2 Hz, 2H); 9.16 (bs, 2H, OH); 9.31 (bs, 1H, OH).  
13C NMR (DMSO-d6, 100 MHz): δ  27.8 (t); 42.4 (t); 50.4 (q); 54.5 (q); 108.8 (d); 113.8 (2d); 114.8 (d); 
115.0 (2d); 117.0 (s); 118.8 (s); 120.7 (s); 125.5 (s); 125.6 (s); 126.3 (s); 130.8 (s); 131.2 (2d); 131.9 
(2d); 132.2 (s); 145.6 (s); 145.7 (s); 155.4 (s); 155.9 (s); 161.5 (s).  MS (MALDI-TOF) m/z 457 (M).  
HRMS m/z calcd. for C27H23NO6  457.1525, found. 457.1520 
Methyl 8-hydroxy-1,2-bis(3-hydroxyphenyl)-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate (14k). Following the general procedure G and starting from 7k (18.6 mg, 0.032 mmol), 
elution with hexane/ AcOEt (60:40 to AcOEt) gave 14k (12.3 mg, 85%) as a white solid. M. p. (MeCN) 
128-130 ºC.  IR (film) ν 3299, 1680, 1440, 1202 cm-1.  1H NMR (DMSO-d6, 400 MHz) δ 2.94 (t, J = 
6.5 Hz, 2H, H6); 3.20 (s, 3H, OMe); 3.49 (s, 3 H, CO2Me); 4.43 (m, 2H, H5); 6.39 (s, 1H); 6.48-6.50 
(m, 2H); 6.52-6.55 (m, 3H); 6.9-6.64 (m, 1H); 6.94-6.98 (t, J = 8.1Hz, 1H); 7.06-7.10 (t, J = 8.4Hz, 
1H); 6.68 (s, 1H); 9.11 (bs, 1H, OH); 9.17 (bs, 1H, OH); 9.27 (bs, 1H, OH).  13C NMR (DMSO-d6, 100 
MHz)   δ 27.8 (t); 42.5 (t); 50.6 (q); 54.4 (q); 108.8 (d); 113.1 (d); 113.6 (d); 114.8 (d); 117.1 (d); 117.3 
(d); 118.5 (s); 120.5 (s); 121.0 (d);  121.6 (d); 126.3 (s); 127.7 (d); 129.1 (d); 130.5 (s); 131.6 (s); 136.2 
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(s); 136.5 (s); 145.7 (s); 145.9 (s); 155.9 (s); 157.1 (s); 161.4 (s).  MS (MALDI-TOF) m/z 457 (M).  
HRMS m/z calcd. for C27H23NO6  457.1525, found 457.1520. 
Methyl 1,2-bis(4-dimethylaminophenyl)-8-hydroxy-9-methoxy-5,6-dihydropyrrolo[2,1-
a]isoquinoline-3-carboxylate (14l).  Following the general procedure G and starting from 11l (5.4 mg, 
0.0098 mmol), elution with hexane/ AcOEt (80:20 to 50:50) gave 14l (2.3 mg, 46 %) as a white solid.  
M. p. (MeCN)  245-247 ºC.  IR (film) ν  cm-1.  1H NMR (CDCl3, 400 MHz) δ 2.88 (s, 6H, NMe2); 2.91 
(s, 6H, NMe2); 2.99 (t, J = 6.5 Hz, 2H, H6); 3.35 (s, 3H, OMe); 3.62 (s, 3H, CO2Me); 4.56 (t, J = 6.5 
Hz, 2H, H5); 5.48 (bs, 1H, OH); 6.54 (s, 1H); 6.59 (d, J = 8.8 Hz, 2H); 6.64 (d, J = 8.8 Hz, 2H); 6.74 
(s, 1H); 7.01 ( d, J = 8.8 Hz, 2H); 7.02 (d, J = 8.8 Hz, 2H).  13C NMR (CDCl3, 100 MHz): δ  28.9 (t); 
40.5 (t); 40.5 (q); 40.7 (q); 50.7 (q); 55.2 (q); 108.3 (d); 111.4 (2d); 112.8 (2d); 113.4 (d); 117.6 (s); 
120.8 (s); 121.7 (s); 121.9 (s); 123.9 (s); 126.7 (s); 131.2 (2d); 131.4 (s); 131.9 (2d); 144.4 (s); 144.6 (s); 
146.6 (s); 149.8 (s); 161.1 (s).  MS (MALDI-TOF) m/z 511 (M); 512 (M+1).  HRMS m/z calcd. for 
C31H33N3O4  511.2471, found. 511.2466. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(3-nitrophenyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-
carboxylate (14m). Following the general procedure G and starting from 7m (42.2 mg, 0.076 mmol), 
elution with hexane/ AcOEt (80:20 to 50:50) gave 14m (17.0 mg, 44%) as a reddish solid. M. p. 
(MeCN) 241-243 ºC. IR (film) ν 2926, 1701, 1540, 1439, 1350, 1227 cm-1. 1H NMR (CDCl3, 400 MHz) 
δ 3.06 (t, J = 6.5 Hz, 2H, H6); 3.29 (s, 3H, OMe); 3.59 (s, 3H, CO2Me); 4.66 (t, J = 6.5 Hz, 2H, H5); 
5.63 (bs, 1H, OH); 6.33 (s, 1H); 6.83 (s, 1H); 7.36-7.50 (m, 4H); 8.00-8.02 (m, 2H); 8.05-8.08 (m, 2H).  
13C NMR (CDCl3, 100 MHz): δ 28.7 (t); 43.0 (t); 51.1 (q); 55.3 (q); 107.8 (d); 114.2 (d); 118.6 (s); 
118.7 (s); 121.7 (d); 121.8 (d); 125.5 (d); 125.8 (d); 127.4 (s); 128.2 (d); 129.4 (d); 130.1 (s); 131.9 (s); 
136.6 (d); 136.9 (s); 137.4 (d); 145.1 (s); 145.6 (s) 147.5 (s); 148.2 (s); 161.4 (s).  MS (MALDI-TOF) 
m/z 515 (M); 516 (M+1).  HRMS m/z calcd. for C27H21N3O8  515.1329, found. 515.1323. 
Methyl 2-(2,4-dihydroxy-5-methoxyphenyl)-8-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-
methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (15d).  Following the general 
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procedure G and starting from 9d (48 mg, 0.07 mmol), elution with hexane/ AcOEt (60:40 to 40:60) 
gave a reddish oil (26 mg, 70%).  IR (film) ν 3419, 1686, 1439, 1246, 1197 cm-1.  1H NMR (CDCl3, 400 
MHz) δ 2.95-3.15 (m, 2H, H6); 3.40 (s, 3H, OMe); 3.54 (s, 3H, OMe); 3.63 (s, 3H, OMe); 3.71 (s, 3H, 
OMe); 4.15-4.25 (m, 2H, H5); 5.54 (s, 3H, 3OH); 5.63 (s, 1H, OH); 6.31 (bs, 1H); 6.53 (bs, 1H, H2’); 
6.56 (s, 1H); 6.72 (s, 1H); 6.75-6.79 (m, 2H); 6.82 (d, J = 8.0 Hz, 1H, H5’).  13C NMR (CDCl3, 100 
MHz) δ  28.8 (t); 43.2 (t); 51.5 (q); 55.5 (q); 55.9 (q); 56.4 (q); 102.8 (d); 108.5 (d); 113.4 (d); 113.8 
(d); 114.0 (d); 114.3 (d); 118.9 (s); 120.0 (s); 122.5 (s); 123.8 (d); 126.8 (s); 126.9 (2s); 127.3 (s); 132.4 
(s); 140.2 (s); 144.4 (s); 145.0 (s); 145.2 (s); 145.7 (s); 146.4 (s); 148.7 (s); 162.4 (s).  MS (MALDI-
TOF) 533 (M, 100); 534 (M+1, 70); 535 (M+2, 32).  HRMS m/z calcd. for C29H27NO9  533.1686, found 
533.1680. 
Methyl 2-(2,5-dimethoxy-4-hydroxyphenyl)-8-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-
methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (15e).  Following the general 
procedure G and starting from  9e (67 mg, 0.10 mmol), elution with hexane/ AcOEt (60:40 to 40:60) 
gave a brown solid (24 mg, 45%).  M. p.  (MeCN) 140-145 ºC.  IR (film) ν 3423, 1688, 1265, 1196 cm-
1. 1H NMR (CDCl3, 400 MHz) δ 3.02 (bs, 2H, H6); 3.38 (s, 3H, OMe); 3.57 (s, 3H, OMe); 3.60 (s, 6H, 
2OMe); 3.63 (s, 3H, OMe); 4.57 (bs, 2H, H5); 5.53 (s, 1H, OH); 5.57 (s, 1H, OH); 5.59 (s, 1H, OH); 
6.50 (s, 2H); 6.59 (s, 1H); 6.66 (s, 1H); 6.74-6.79 (m, 2H); 6.81 (d,  J = 8.0 Hz, 1H, H5’).  13C NMR 
(CDCl3, 100 MHz) δ 28.8 (t); 42.8 (t); 50.8 (q); 55.4 (q); 55.9 (q); 56.2 (q); 56.5 (q); 98.8 (d); 108.3 (d); 
113.5 (d); 113.7 (d); 113.9 (d); 115.1 (d); 115.6 (s); 118.8 (s); 120.6 (s); 121.4 (s); 123.9 (d); 126.7 (s); 
127.8 (s); 128.0 (s); 130.5 (s); 131.1 (s); 135.0 (s); 139.6 (s); 144.1 (s); 144.9 (s); 146.1 (s); 151.9 (s); 
162.5 (s).  MS (MALDI-TOF) 547 (M, 100); 548 (M+1, 30). HRMS m/z calcd. for C30H29NO9  
547.1842, found 547.1837. 
Methyl 1-(2,5-dimethoxyphenyl)-8-hydroxy-9-methoxy-2-(2,4,5-trihydroxyphenyl)-5,6-
dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (15g). Following the general procedure G and 
starting from 9g (22 mg, 0.03 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a reddish oil (7 
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mg, 42%).  IR (film) ν 3425, 1697, 1465, 1243 cm-1.  1H NMR (CDCl3, 400 MHz) δ 2.99 (t, J = 6.4 Hz, 
2H, H6); 3.41 (s, 3H, OMe); 3.65 (s, 3H, OMe); 3.75 (s, 3H, OMe); 3.83 (s, 3H, OMe); 4.61 (t, J = 6.4 
Hz, 2H, H5); 5.12 (bs, 1H, OH); 5.34 (bs, 1H, OH); 5.54 (bs, 1H, OH); 5.78 (bs, 1H, OH); 6.67 (s, 1H); 
6.75 (s, 1H); 6.84 (dd, J = 8.9, 2.8 Hz, 1H, H4’); 6.88 (s, 1H); 6.89-6.92 (m, 2H); 7.02 (s, 1H).  13C 
NMR (CDCl3, 100 MHz) δ 30.9 (t); 42.5 (t); 51.0 (q); 55.4 (q); 55.8 (q); 56.2 (q); 107.6 (d); 112.2 (d); 
113.5 (d); 113.6 (d); 116.7 (s); 117.4 (d); 119.9 (d); 120.1 (s); 121.1 (s); 126.3 (d); 126.5 (s); 132.7 (s); 
144.8 (s); 145.0 (s); 149.8 (s); 150.3 (s); 151.6 (s); 153.6 (s); 161.8 (s).  MS (MALDI-TOF) 533 (M, 
100). HRMS m/z calcd. for C29H27NO9  533.1686, found 533.1684. 
Methyl 8-hydroxy-2-(2-hydroxy-4,5-dimethoxyphenyl)-1-(3-hydroxyphenyl)-9-methoxy-5,6-
dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (15i). Following the general procedure G and 
starting from 9i (23 mg, 0.04 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a reddish oil 
(16 mg, 85%).  IR (film) ν 3405, 1684, 1437, 1196 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.01 (t, J = 6.8 
Hz, 2H, H6); 3.36 (s, 3H, OMe); 3.60 (s, 3H, OMe); 3.81 (s, 3H, OMe); 3.85 (s, 3H, OMe); 4.46-4.71 
(m, 2H, H5); 4.93 (bs, 1H, OH); 5.55 (bs, 1H, OH); 5.74 (bs, 1H, OH); 6.30 (d, J = 8.6 Hz, 1H); 6.53 (s, 
1H); 6.60 (d, J = 8.6 Hz, 1H); 6.64-6.68 (m, 2H); 6.76 (s, 1H); 6.78 (d, J = 7.2 Hz, 1H); 7.11 (t, J = 7.2 
Hz, 1H, H5’).  13C NMR (CDCl3, 100 MHz) δ 28.8 (t); 43.0 (t); 51.0 (q); 55.3 (q); 55.6 (q); 60.9 (q); 
102.9 (d); 108.4 (d); 113.5 (d); 113.7 (d); 115.8 (s); 117.6 (d); 118.9 (d); 120.3 (s); 121.6 (s); 123.6 (d); 
126.1 (d); 126.8 (s); 127.0 (s); 129.3 (s); 131.6 (s); 135.3 (s); 137.2 (s); 144.8 (s); 144.9 (s); 147.5 (s); 
151.4 (s); 155.5 (s); 162.3 (s). MS (MALDI-TOF) 517 (M, 100).  HRMS m/z calcd. for C29H27NO8  
517.1737, found 517.1731.  
Methyl 8-hydroxy-9-methoxy-1-(3,4,5-trimethoxyphenyl)pyrrolo[2,1-a]isoquinoline-3-carboxylate 
(16a). Following the general procedure G and starting from 10a (23 mg, 0.05 mmol), elution with 
hexane/ AcOEt (80:20 to 70:30) gave a yellowish solid (13 mg, 70%). M. p. (MeCN) 212-213 ºC. IR 
(film) ν 3409, 1678, 1207 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.57 (s, 3H, OMe); 3.86 (s, 6H, 2OMe); 
3.91 (s, 3H, OMe); 3.92 (s, 3H, OMe); 5.82 (bs, 1H, OH); 6.75 (s, 2H, H2’, H6’); 6.94 (d, J = 7.6 Hz, 
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1H, H6); 7.14 (s, 1H); 7.31 (s, 1H); 7.42 (s, 1H); 9.22 (d, J = 7.6 Hz, 1H, H5).  13C NMR (CDCl3, 100 
MHz): δ  51.2 (q); 55.5 (q); 56.2 (2q); 60.9 (q); 104.5 (d); 107.4 (2d); 110.5 (d); 112.5 (d); 114.1 (s); 
118.1 (s); 119.4 (s); 121.8 (d); 123.5 (s); 124.1 (d); 130.8 (s); 132.9 (s); 137.2 (s); 146.0 (s); 146.7 (s); 
153.3 (2s); 161.8 (s).  MS (EI) m/z 393 (M, 100); 394 (M+1, 12).  MS (ESI-TOF) m/z 438 (M+1, 100).  
HRMS m/z calcd. for C24H24NO7 438.1547, found 438.1547. 
Methyl 8-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-methoxypyrrolo[2,1-a]isoquinoline-3-
carboxylate (16c). Following the general procedure G and starting from 10d (23 mg, 0.05 mmol), 
elution with hexane/ AcOEt (80:20 to 70:30) gave a yellowish solid (13 mg, 70%). M. p. (MeCN) 163-
165 ºC. IR (film) ν 1691, 1464, 1267, 1094 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.56 (s, 3H, OMe); 
3.90 (s, 3H, OMe); 3.91 (s, 3H, OMe); 5.71 (bs, 1H, OH); 5.84 (bs, 1H, OH); 6.92 (d, J = 7.6 Hz, 1H, 
H6); 7.00 (d, J = 1.2 Hz, 1H, H2’); 7.03-7.05 (m, 2H, H5’, H6’); 7.12 (s, 1H); 7.33 (s, 1H); 7.39 (s, 1H); 
9.21 (d, J = 7.6 Hz, 1H, H5). 13C NMR (CDCl3, 100 MHz): δ  51.1 (q); 55.5 (q); 56.0 (q); 104.5 (d); 
110.5 (d); 112.3 (d); 113.0 (d); 114.0 (s); 114.3 (d); 116.2 (d); 118.1 (s); 119.6 (s); 122.2 (d); 123.5 (d); 
124.0 (s); 129.1 (s); 130.9 (s); 144.9 (s); 145.9 (s); 146.5 (s); 146.7 (s); 161.8 (s).  MS (EI) m/z 393 (M, 
100); 394 (M+1, 12).  HRMS m/z calcd. for C27H19N3O8  393.1212, found 393.1215. 
Methyl 1-(2,5-dimethoxyphenyl)-8-hydroxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate 
(16e). Following the general procedure G and starting from 10e (26 mg, 0.06 mmol), elution with 
hexane/ AcOEt (80:20 to 70:30) gave a yellow solid (14 mg, 57%). M. p. (MeCN) 198-199 ºC.  IR 
(film) ν 1690, 1465, 1206 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.53 (s, 3H, OMe); 3.64 (s, 3H, OMe); 
3.79 (s, 3H, OMe); 3.90 (s, 3H, OMe); 5.80 (s, 1H, OH); 6.93 (d, J = 7.6 Hz, 1H, H6); 6.94 (dd, J = 8.4, 
2.8 Hz, 1H, H4’); 6.97 (d, J = 8.4 Hz, 1H, H3’); 6.99 (d, J = 2.8 Hz, 1H, H6’); 7.12 (s, 1H); 7.14 (s, 
1H); 7.43 (s, 1H); 9.23 (d, J = 7.6 Hz, 1H, H5).  13C NMR (CDCl3, 100 MHz): δ  51.1 (q); 55.4 (q); 55.8 
(q); 56.3 (q); 104.4 (d); 110.2 (d); 112.1 (d); 112.4 (d); 113.4 (s); 114.0 (d); 114.3 (s); 117.9 (d); 120.0 
(s); 122.4 (d); 123.6 (d); 124.0 (s); 127.0 (s); 131.5 (s); 145.8 (s); 146.8 (s); 152.2 (s); 153.6 (s); 161.8 
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(s).   MS (MALDI-TOF) m/z 407 (M, 100); 408 (M+1, 40).  HRMS m/z calcd. for C23H21NO6 407.1369, 
found 407.1363. 
Methyl 8-hydroxy-9-methoxy-1-(2-thienyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate 
(16n). Following the general procedure G and starting from 6n (15 mg, 0.04 mmol), elution with 
hexane/ AcOEt (90:10) gave a white solid (6 mg, 45%). M. p. (MeCN) 134-136 ºC . IR (film) ν 3420, 
1693, 1466, 1207 cm-1.  1H NMR (CDCl3, 200 MHz) δ 3.62 (s, 3H, OMe); 3.91 (s, 3H, OMe); 5.82 (s, 
1H, OH); 6.95 (d, J = 7.5 Hz, 1H, H6); 7.14 (s, 1H); 7.16 (s, 1H); 7.17 (d, J = 2.0 Hz, 1H); 7.34-7.35 
(bd, 1H); 7.44 (dd, J = 4.1, 2.0 Hz, 1H); 7.48 (s, 1H); 9.22 (d, J = 7.5 Hz, 1H, H5).  13C NMR (CDCl3, 
100 MHz): δ  51.2 (q); 55.5 (q); 104.3 (d); 109.1 (s); 110.4 (d); 112.7 (d); 114.3 (s); 119.3 (s); 123.4 (d); 
123.5 (d); 124.2 (s); 126.2 (d); 127.3 (d); 128.0 (d); 132.0 (s); 138.3 (s); 146.2 (s); 146.9 (s); 161.7 (s).  
MS (MALDI-TOF) m/z 353 (M, 100). MS (ESI-TOF) m/z 354 (M+1, 100).  HRMS m/z calcd. for 
C19H16NO4S 354.0795, found 354.0795. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(3,4,5-trimethoxyphenyl)pyrrolo[2,1-a]isoquinoline-3-
carboxylate (17a). Following the general procedure G and starting from 11a (41 mg, 0.06 mmol), 
elution with hexane/ AcOEt (60:40 to 40:60) gave a reddish oil (25 mg, 65%).  IR (film) ν 3404, 1682, 
1377, 1235 cm-1.  1H NMR (CDCl3, 400 MHz) δ  3.51 (s, 3H, OMe); 3.69 (s, 6H, 2OMe); 3.70 (s, 6H, 
2OMe); 3.72 (s, 3H, OMe); 3.84 (s, 3H, OMe); 3.85 (s, 3H, OMe); 5.82 (bs, 1H, OH); 6.46 (s, 2H); 6.53 
(s, 2H); 6.95 (d, J = 7.6 Hz, 1H, H6); 7.14 (s, 1H); 7.15 (s, 1H); 9.30 (d, J = 7.6 Hz, 1H, H5).  13C NMR 
(CDCl3, 100 MHz) δ 50.9 (q); 55.3 (q); 56.0 (2q); 56.2 (2q); 60.88 (q); 60.92 (q); 104.8 (d); 108.3 (2d); 
108.9 (2d); 110.4 (d); 111.8 (s); 112.4 (d); 118.2 (s); 119.0 (s); 123.6 (d); 124.4 (s); 126.9 (s); 130.5 (s); 
131.7 (s); 135.3 (s); 136.8 (s); 137.1 (s); 146.0 (s); 146.7 (s); 152.0 (2s); 153.2 (2s); 162.4 (s). MS 
(MALDI-TOF) m/z 603 (M, 100); 604 (M+1, 80).  HRMS m/z calcd. for C33H33NO10 603.2105, found 
603.2099. 
Methyl 8-hydroxy-1,2-bis(4-hydroxy-3-methoxyphenyl)-9-methoxypyrrolo[2,1-a]isoquinoline-3-
carboxylate (17c). Following the general procedure G and starting from 11c (46 mg, 0.08 mmol), a 
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yellow solid (26 mg, 61%).  M. p. (MeCN) 235-237 ºC.  IR (film) ν 3415, 1680, 1376, 1211 cm-1.  1H 
NMR (CDCl3, 400 MHz) δ 3.49 (s, 3H, OMe); 3.67 (s, 3H, OMe); 3.68 (s, 3H, OMe); 3.69 (s, 3H, 
OMe); 5.50 (bs, 1H, OH); 5.58 (bs, 1H, OH); 5.79 (bs, 1H, OH); 6.66 (d, J = 1.6 Hz, 2H, H2’, H2”); 
6.72-6.77 (m, 2H, H6’, H6”); 6.80 (d, J = 8.0 Hz, 1H, H6); 6.91 and 6.92 (2d, J = 8.6 Hz, 2H, H5’, 
H5”); 7.12 (s, 1H); 7.13 (s, 1H); 9.30 (d, J = 8.0 Hz, 1H, H5).  13C NMR (CDCl3, 100 MHz): δ  50.8 (q); 
55.4 (q); 55.8 (q); 56.0 (q); 104.8 (d); 110.3 (d); 112.1 (d); 113.2 (d); 113.5 (d); 114.2 (d); 114.4 (d); 
118.4 (s); 119.3 (s); 123.7 (d); 124.1 (d); 124.3 (s); 125.0 (d); 127.2 (s); 128.0 (s); 130.6 (s); 135.8 (s); 
144.2 (s); 144.7 (s); 145.3 (s); 145.9 (s); 146.4 (s); 146.5 (s); 162.6 (s).  MS (MALDI-TOF) 515 (M, 
100); 516 (M+1, 80).  HRMS m/z calcd. for C29H25NO8  515.1580, found 515.1575. 
Methyl 1,2-bis(3,4-dimethoxyphenyl)-8-hydroxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-
carboxylate (17f). Following the general procedure G and starting from 11f (22 mg, 0.04 mmol), 
elution with hexane/ AcOEt (60:40 to 40:60) gave a yellowish oil (10 mg, 49%).  IR (film) 
ν 3342, 1599 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.47 (s, 3H, OMe); 3.68 (s, 3H, OMe); 3.70 (s, 3H, 
OMe); 3.71 (s, 3H, OMe); 3.87 (s, 3H, OMe); 3.88 (s, 3H, OMe); 5.79 (bs, 1H, OH); 6.70-6.78 (m, 4H); 
6.85 (s, 2H); 6.92 (d, J = 7.6 Hz, 1H, H6); 7.11 (s, 1H); 7.12 (s, 1H); 9.29 (d, J = 7.6 Hz, 1H, H5).  13C 
NMR (CDCl3, 100 MHz) δ 50.7 (q); 55.3 (q); 55.6 (q); 55.7 (q); 55.8 (q); 55.9 (q); 104.8 (d); 109.9 (d); 
110.3 (d); 111.1 (d); 111.9 (s); 112.1 (d); 114.2 (d); 115.0 (d), 118.3 (s); 119.3 (s), 123.2 (d); 123.7 (d); 
124.2 (d);  124.3 (s); 127.8 (s); 128.7 (s); 130.6 (s); 135.7 (s); 145.9 (s); 146.5 (s); 147.5 (s); 147.5 (s); 
148.0 (s); 148.9 (s); 162.6 (s).  MS (MALDI-TOF) m/z 543 (M); 544 (M+1).  HRMS m/z calcd. for 
C31H29NO8  543.1893, found 543.1888. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(4-methoxyphenyl)pyrrolo[2,1-a]isoquinoline-3-carboxylate 
(17g).  Following the general procedure G and starting from 11g (42 mg, 0.08 mmol), elution with 
hexane/ AcOEt (60:40 to 40:60) gave a pale solid (27 mg, 71%).  M. p. (MeCN)  241-4 ºC.  IR (film) 
ν 2951, 1676 cm-1.  1H NMR (DMSO-d6, 400 MHz) δ 3.28 (s, 3H, OMe); 3.54 (s, 3H, OMe); 3.71 (s, 
3H, OMe); 3.74 (s, 3H, OMe); 6.77 (d, J = 8.6 Hz, 2H); 6.80 (s, 1H); 6.96 (d, J = 8.6 Hz, 2H); 7.08-7.11 
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(m, 3H); 7.11 (s, 1H); 7.19 (d, J = 8.5 Hz, 2H); 9.14 (d, J = 7.6 Hz, 1H, H5); 9.67 (bs, 1H, OH).  13C 
NMR (DMSO-d6, 100 MHz) δ 50.5 (q); 54.3 (q); 54.7 (q); 55.0 (q); 104.7 (d), 111.1 (d); 111.9 (d); 
112.3 (2d); 113.8 (2d); 117.6 (s); 117.8 (s), 122.5 (s); 123.4 (d); 126.9 (s); 127.4 (s); 130.0 (s); 131.3 
(2d); 132.8 (2d); 134.9 (s); 147.2 (s); 148.0 (s); 157.6 (s); 158.3 (s); 161.6 (s).  MS (MALDI-TOF) m/z 
483 (M).  HRMS m/z calcd. for C29H25NO6  483.1682, found. 483.1676. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(4-trifluoromethoxyphenyl)pyrrolo[2,1-a]isoquinoline-3-
carboxylate (17i). Following the general procedure G and starting from 11i (29 mg, 0.05 mmol), 
elution with hexane/ AcOEt (60:40 to 40:60) gave a reddish oil (8 mg, 30%).  IR (film) ν 1727 cm-1.  1H 
NMR (Acetone-d6, 400 MHz) δ 3.26 (s, 3H, OMe); 3.46 (s, 3H, OMe); 6.75 (s, 1H); 7.01 (d, J = 7.6 Hz, 
1H, H6); 7.06 (d, J = 8.0 Hz, 2H); 7.09 (s, 1H); 7.23 (d, J = 8.7 Hz, 2H); 7.26 (d, J = 8.0 Hz, 2H); 7.36 
(d, J = 8.7 Hz, 2H); 8.23 (bs, 1H, OH); 9.18 (d, J = 7.6 Hz, 1H, H5).  13C NMR (Acetone-d6, 100 MHz)  
δ 49.4 (q); 53.5 (q); 103.9 (d), 110.6 (d); 111.5 (q); 111.9 (d); 116.0 (q); 117.7 (s); 118.8 (2d); 120.6 
(2d); 122.2 (s); 123.6 (s); 129.7 (d); 131.6 (s); 133.1 (2d); 133.5 (2d); 133.9 (s); 134.7 (s); 146.9 (s); 
147.1 (s); 147.5 (s); 147.6 (s); 161.0 (s).  MS (MALDI-TOF) m/z 591 (M).  HRMS m/z calcd. for 
C29H19F6NO6  591.1117, found. 591.1111. 
Methyl 8-hydroxy-1,2-bis(4-hydroxyphenyl)-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate 
(17j). Following the general procedure G and starting from 11j (77 mg, 0.18 mmol), elution with 
hexane/ AcOEt (60:40 to 40:60) gave a pale solid (32 mg, 53%).   M. p. (MeCN)   280-4 ºC.  IR (film) 
ν 3373, 1684 cm-1.  1H NMR (DMSO-d6, 400 MHz) δ 3.29 (s, 3H, OMe); 3.54 (s, 3H, OMe); 6.58 (d, J 
= 8.5 Hz, 2H); 6.77 (d, J = 8.5 Hz, 2H); 6.90 (s, 1H); 6.95 (d, J = 8.5 Hz, 2H); 7.03 (s, 1H); 7.05-7.08 
(m, 3H); 9.12 (d, J = 7.6 Hz, 1H, H5); 9.22 (bs, 1H, OH); 9.42 (bs, 1H, OH); 9.64 (bs, 1H, OH).  13C 
NMR (DMSO-d6, 100 MHz) δ 50.4 (q); 54.3 (q); 104.9 (d);  110.9 (d); 111.7 (d); 113.8 (2d); 115.2 (2d);  
117.9 (s); 118.0 (s), 122.5 (s);  123.3 (d); 125.3 (s); 125.7 (s); 130.0 (s); 131.3 (2d); 132.7 (2d); 135.5 
(s); 147.1 (s); 147.9 (s); 155.7 (s); 156.4 (s); 161.7 (s).  MS (MALDI-TOF) m/z 455 (M, 100).  HRMS 
m/z calcd. for C27H21NO6  455.1369, found 455.1363. 
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Methyl 8-hydroxy-1,2-bis(3-hydroxyphenyl)-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate 
(17k, R3 = OH). Following the general procedure G and starting from 11k (67 mg, 0.12 mmol), elution 
with hexane/ AcOEt (60:40 to 40:60) gave a pale solid (24 mg, 46%).  M. p. (MeCN)  260-265 ºC.  IR 
(film) ν 3384, 1653 cm-1.  1H NMR (DMSO-d6,  400 MHz) δ 3.29 (s, 3H, OMe); 3.53 (s, 3H, CO2Me); 
6.66-6.76 (m, 3H); 6.72 (t, J = 1.8 Hz, 1H); 6.70-6.72 (dd, J = 7.8, 1.9 Hz, 2H); 6.90 (s, 1H); 6.98-7.02 
(dd, J = 8.7, 9.0 Hz, 1H); 7.10 (s, 1H); 7.11 (d, J = 7.6 Hz, 1H, H6); 7.19 (t, J = 8.0 Hz, 1H); 9.11 (d, J 
= 7.6 Hz, 1H, H5); 9.17 (bs, 1H, OH); 9.27 (bs, 1H, OH); 9.40 (bs, 1H, OH).  13C NMR (DMS-d6,  100 
MHz) δ 50.6 (q); 54.3 (q); 104.9 (d), 111.1 (d); 112.1 (d); 113.4 (d); 114.1 (d); 117.2 (d); 117.7 (s); 
117.8 (s); 118.2 (d); 121.1 (d); 122.3 (d); 122.4 (d);  123.4 (s); 127.7 (d); 129.3 (d); 129.5 (s); 134.9 (s); 
136.1 (s); 136.7 (s); 147.2 (s); 148.1 (s); 155.8 (s); 157.2 (s); 161.6 (s).  MS (MALDI-TOF) m/z 455 
(M).  HRMS m/z calcd. for C27H21NO6  455.1369, found. 455.1363. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(3-nitrophenyl)pyrrolo[2,1-a]isoquinoline-3-carboxylate 
(17m). Following the general procedure G and starting from 11m (31 mg, 0.06 mmol), elution with 
hexane/ AcOEt (60:40 to 40:60) gave a pale solid (23 mg, 82%) .  M. p. (MeOH) = 185-190 ºC.  IR 
(film) ν 1689, 1537, 1379, 1348 cm-1.  1H NMR (DMSO-d6, 400 MHz)  3.25 (s, 3H, OMe); 3.56 (s, 3H, 
CO2Me); 6.76 (s, 1H); 7.19 (s, 1H); 7.25 (d, J = 7.6 Hz, 1H, H6); 7.53 (td, J = 7.6, 1.2 Hz, 1H); 7.67-
7.72 (m, 2H); 7.85 (dt, J = 8.0, 1.2 Hz, 1H); 8.08 (d, J = 1.2 Hz, 1H); 8.07 (dt, J = 8.0, 1.2 Hz, 1H); 
8.16-8.19 (m, 2H); 9.22 (d, J = 7.6 Hz, 1H, H5).  13C NMR (DMSO-d6,  100 MHz) δ 50.9 (q); 54.4 (q); 
104.3 (d), 111.5 (d); 111.8 (s); 113.1 (d); 115.2 (s); 117.2 (s), 121.7 (d); 122.3 (d); 122.4 (d); 123.7 (s); 
125.0 (d); 126.0 (d); 128.7 (d); 129.9 (d); 130.0 (s); 132.7 (s); 136.2 (s); 136.6 (s); 137.2 (d); 138.5 (d); 
146.8 (s); 147.7 (s); 147.9 (s); 148.5 (s); 160.9 (s).  MS (MALDI-TOF) m/z  513 (M); 514 (M+1).  
HRMS m/z calcd. for C27H19N3O8  513.1172, found 513.1167. 
Methyl 8-hydroxy-9-methoxy-1,2-bis(2-thienyl)pyrrolo[2,1-a]isoquinoline-3-carboxylate (17n). 
Following the general procedure G and starting from 11n (12 mg, 0.03 mmol), elution with hexane/ 
AcOEt (90:10 to 75:25) gave a pale solid (5 mg, 40%).   M. p. (MeCN) 205-208 ºC.  IR (film) ν 3409, 
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1683, 1434, 1376, 1246 cm-1.  1H NMR (CDCl3, 400 MHz) δ  3.56 (s, 3H, OMe); 3.73 (s, 3H, OMe); 
5.82 (bs, 1H, OH); 6.93-6.95 (m, 2H); 6.96 (d, J = 7.6 Hz, 1H, H6); 7.05 (dd, J = 3.4, 1.2 Hz, 1H); 7.08-
7.11 (m, 2H); 7.13 (s, 1H); 7.26-7.28 (m, 1H); 7.39 (dd, J = 5.2, 1.2, 1H); 9.26 (d, J = 7.6 Hz, 1H, H5).  
13C NMR (CDCl3, 100 MHz): δ  51.0 (q); 55.3 (q); 104.6 (d); 110.3 (d); 110.4 (s); 112.9 (d); 113.2 (s); 
118.9 (s); 123.4 (d); 124.4 (s); 125.8 (d); 126.0 (d); 127.19 (d); 127.24 (d); 128.3 (d); 129.5 (s); 129.9 
(d); 131.8 (s); 135.0 (s); 136.7 (s); 146.2 (s); 146.9 (s); 162.2 (s).  MS (ESI) m/z 436 (M+1, 100); 437 
(M+2, 65). MS (ESI-TOF) m/z 436 (M+1, 100).  HRMS m/z calcd. for C23H18NO4S2 436.0672, found 
436.0672.  
Methyl 8-hydroxy-2-(4-hydroxyphenyl)-1-(4-hydroxy-3-methoxyphenyl)-9-methoxypyrrolo[2,1-
a]isoquinoline-3-carboxylate (18a).  Following the general procedure G and starting from 12a (82 mg, 
0.14 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a pinkish solid (62 mg, 89%).  M. p. 
(MeCN) 260-262 ºC.  IR (film) ν 3364, 1653 cm-1. 1H NMR (MeOD-d4, 400 MHz) δ  3.43 (s, 3H, 
OMe); 3.60 (s, 3H, OMe); 3.67 (s, 3H, OMe); 6.63 (d, J = 8.8 Hz, 2H, H3”, H5”); 6.69-6.72 (m, 2H, 
H2’, H6’); 6.81 (bd, J = 8.0 Hz, 1H, H5’); 6.88 (d, J = 7.6 Hz, 1H, H6); 6.98 (d, J = 8.8 Hz, 2H, H2”, 
H6”); 7.02 (s, 1H); 7.10 (s, 1H); 9.18 (d, J = 7.6 Hz, 1H, H5).  13C NMR (MeOD-d4, 100 MHz) δ  51.0 
(q); 55.7 (q); 56.5 (q); 106.5 (d);  112.1 (d); 112.8 (s); 112.9 (d); 114.9 (2d); 116.3 (d); 116.8 (d); 120.1 
(s); 120.2 (s); 124.3 (d); 125.6 (s); 126.0 (d); 128.2 (s); 128.9 (s); 132.2 (s); 132.9 (2d); 137.8 (s); 146.8 
(s); 148.4 (s); 149.0 (s); 149.3 (s); 157.1 (s); 164.2 (s).  MS (ESI-TOF) 486 (M+1, 67); 486 (MNa+, 
100).  HRMS m/z calcd. for C28H23NNaO7
+
  508.1367, found 508.1367. 
Methyl 2-(3,4-dimethoxyphenyl)-8-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-
methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (18b). Following the general procedure G and 
starting from 12b (66 mg, 0.11 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a yellowish 
solid (38 mg, 67%). M. p. (MeCN) 110-113 ºC. IR (film) ν 3420, 1676 cm-1. 1H NMR (CDCl3, 400 
MHz) δ  3.49 (s, 3H, OMe); 3.68 (s, 3H, OMe); 3.69 (s, 3H, OMe); 3.70 (s, 3H, OMe); 3.87 (s, 3H, 
OMe); 5.58 (bs, 1H, OH); 5.79 (bs, 1H, OH); 6.67 (d, J = 2.0 Hz, 1H); 6.72 (d, J = 1.6 Hz, 1H); 6.75 (d, 
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J = 8.4 Hz, 1H); 6.78 (dd, J = 8.4, 2.0, 1H); 6.89 (dd, J = 8.0, 1.6 Hz, 1H); 6.92 (d, J = 7.6 Hz, 1H, H6); 
6.93 (d, J = 8.0 Hz, 1H); 7.117 (s, 1H); 7.122 (s, 1H); 9.29 (d, J = 7.6 Hz, 1H, H5).  13C NMR (CDCl3, 
100 MHz) δ  50.8 (q); 55.4 (q); 55.7 (2q); 56.0 (q); 104.8 (d); 109.9 (d); 110.3 (d); 111.9 (s); 112.1 (d); 
114.2 (2d); 114.3 (d); 118.4 (s); 119.3 (s), 123.2 (d); 123.7 (d); 124.3 (s); 125.0 (d); 127.8 (s); 128.0 (s); 
130.6 (s); 135.7 (s); 144.7 (s); 145.9 (s); 147.53 (s); 146.4 (s); 146.5 (s); 147.5 (s); 162.8 (s).  MS 
(MALDI-TOF) 529 (M, 100).  HRMS m/z calcd. for C30H27NO8  529.1737, found 529.1731. 
Methyl 1-(3,5-dimethoxy-4-hydroxyphenyl)-8-hydroxy-9-methoxy-2-(3,4,5-
trimethoxyphenyl)pyrrolo[2,1-a]isoquinoline-3-carboxylate (18c R4 of 2-Ar = OH).  Following the 
general procedure G and starting from 12c (80 mg, 0.12 mmol) using an excess of AlCl3 (0.32 mmol), 
elution with hexane/ AcOEt (60:40 to 40:60) gave a yellowish solid (61 mg, 96%). M. p. (MeCN)  163-
166 ºC. IR (film) ν 3421, 1678 cm-1. 1H NMR (CDCl3, 400 MHz) δ  3.49 (s, 3H, OMe); 3.69 (s, 3H, 
OMe); 3.70 (s, 3H, OMe); 3.72 (s, 6H, 2OMe); 5.44 (s, 1H, OH); 5.60 (s, 1H, OH); 5.80 (s, 1H, OH);  
6.45 (s, 2H, H2”, H6”); 6.66 (d, J = 1.6 Hz, 1H, H2’); 6.91 (dd, J = 8.4, 1.6 Hz, 1H, H6’); 6.93 (d, J = 
7.6 Hz, 1H, H6); 6.95 (d, J = 8.4 Hz, 1H, H5’); 7.13 (s, 2H, H7, H10); 9.30 (d, J = 7.6 Hz, 1H, H5).  13C 
NMR (CDCl3, 100 MHz) δ. 50.8 (q); 55.4 (q); 56.0 (q); 56.2 (2q); 104.8 (d); 108.0 (2d); 110.3 (d); 111.7 
(s); 112.2 (d); 114.20 (d); 114.23 (d), 118.3 (s); 119.2 (s), 123.6 (d); 124.3 (s); 125.0 (d); 126.2 (s); 
128.1 (s); 130.6 (s); 133.4 (s); 135.7 (s); 144.7 (s); 145.90 (s); 145.93 (2s); 146.5 (s); 146.6 (s); 162.6 
(s).  MS (ESI-TOF) 514 (M, 26); 568 (M+Na, 100).  HRMS m/z calcd. for C30H27NNaO9
+
  568.1578, 
found 568.1578. 
Methyl 2-(2,4-dihydroxy-5-methoxyphenyl)-8-hydroxy-1-(4-hydropoxy-3-methoxyphenyl)-9-
methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (18d).  Following the general procedure G and 
starting from 12d (97 mg, 0.14 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a light brown 
solid (63 mg, 86%). M. p. (MeCN)  163-166 ºC.  IR (film) ν 3426, 1679 cm-1.  1H NMR (CDCl3, 400 
MHz) δ 3.51 (s, 3H, OMe); 3.55 (s, 3H, OMe); 3.66 (s, 3H, OMe); 3.77 (s, 3H, OMe); 5.43 (br, 1H, 
OH); 5.56 (s, 1H, OH); 5.61 (s, 1H, OH); 5.87 (s, OH); 6.33-6.92 (m, 3H); 6.92-7.27 (m, 5H); 9.19 (m, 
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1H, H5).  13C NMR (CDCl3, 100 MHz) δ 51.4 (q); 55.4 (q); 56.0 (q); 56.4 (q); 102.7 (d); 104.8 (d); 
110.4 (d); 112.5 (d); 112.7 (s); 113.8 (d); 113.9 (s); 114.0 (d);  114.1 (d); 119.1 (s); 123.4 (d); 124.2 (d); 
124.5 (s); 131.3 (s); 140.2 (s); 144.8 (s); 145.8 (s); 146.1 (s); 146.6 (s); 146.7 (s); 148.6 (s); 162.3 (s).  
MS (MALDI-TOF) 531 (M, 100), 532 (M+1, 38), 533 (M+2, 11).  HRMS m/z calcd. for C29H25NO9  
531.1529, found 531.1524. 
Methyl 2-(2,5-dimethoxy-4-hydroxyphenyl)-8-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-
methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (18e). Following the general procedure G and 
starting from 12e (51 mg, 0.08 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a reddish 
solid (21 mg, 50%).  M. p. (MeCN)  149-151 ºC.  IR (film) ν 3389, 1681, 1438, 1206 cm-1. 1H NMR 
(CDCl3, 400 MHz) δ  3.50 (s, 3H, OMe); 3.61 (bs, 3H, OMe); 3.65 (2s, 6H, 2OMe); 3.70 (s, 3H, OMe); 
5.56 (bs, 2H, 2OH); 5.78 (s, 1H, OH); 6.51 (s, 1H); 6.55 (bs, 1H); 6.72 (bs, 1H); 6.85-6.93 (m, 3H); 
7.11 (s, 1H); 7.18 (s, 1H); 9.25 (d, J = 7.6 Hz, 1H, H5).  13C NMR (CDCl3, 100 MHz) δ  50.8 (q); 55.4 
(q); 55.9 (q); 56.0 (q); 56.6 (q); 98.8 (d); 104.8 (d); 110.3 (d); 111.9 (d); 114.1 (d); 115.0 (d); 115.6 (d); 
118.5 (s); 119.4 (s); 123.7 (d); 124.1 (s); 124.6 (d); 124.7 (s); 128.2 (s); 130.5 (s); 139.6 (s); 144.5 (s); 
145.2 (s); 145.7 (2s); 146.5 (2s); 152.0 (s); 162.6 (s).  MS (MALDI-TOF) 545 (M, 100); 546 (M+1, 70).  
HRMS m/z calcd. for C30H27NO9  545.1686, found 545.1680. 
 
 Methyl 1-(2,5-dimethoxyphenyl)-8-hydroxy-9-methoxy-2-(2,4,5-trihydroxyphenyl)pyrrolo[2,1-
a]isoquinoline-3-carboxylate (18g).  Following the general procedure G and starting from 12g (31 mg, 
0.04 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a reddish solid (15 mg, 62%).  M. p. 
(MeCN) 149-150 ºC.  IR (film) ν 3418, 1690, 1466, 1208  cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.53 (s, 
3H, OMe); 3.65 (s, 3H, OMe); 3.79 (s, 3H, OMe); 3.90 (s, OMe); 6.91-6.99 (m, 5H, H6, H7, H3’, H4’, 
H6’); 7.12 (s, 1H, H3”); 7.14 (s, 1H); 7.43 (s, 1H, H6”); 9.22 (d, J = 7.6 Hz, 1H, H5).  13C NMR 
(CDCl3, 100 MHz) δ 51.1 (q); 53.4 (q); 55.8 (q); 56.3 (q); 104.4 (d); 107.2 (d); 110.2 (d); 112.1 (d); 
112.4 (d); 113.4 (s); 114.0 (d); 114.3 (s); 117.9 (d); 120.0 (s); 122.4 (d); 123.6 (d); 123.9 (s); 127.0 (s); 
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130.8 (s); 131.5 (s); 145.8 (s); 146.8 (s); 152.2 (s); 152.8 (s); 153.4 (s); 153.6 (s); 153.7 (s); 161.8 (s).   
MS (MALDI-TOF) 531 (M, 100).  HRMS m/z calcd. for C30H27NO9  531.1529, found 531.1527. 
Methyl 2-(2,4-dihydroxyphenyl)-8-hydroxy-1-(3-hydroxyphenyl)-9-methoxypyrrolo[2,1-
a]isoquinoline-3-carboxylate (18h). Following the general procedure G and starting from 12h (27 mg, 
0.04 mmol), elution with hexane/ AcOEt (60:40 to 40:60) gave a yellow solid (8 mg, 40%). M. p. 167-
169 ºC.  IR (film) ν 3374, 1683, 1207 cm-1.  1H NMR (CDCl3, 400 MHz) δ 3.57 (s, 3H, OMe); 3.91 (s, 
3H, OMe); 6.86-6.89 (m, 1H); 6.91 (d, J = 7.6 Hz, 1H, H6); 6.97-7.00 (m, 3H); 6.98-7.02 (m, 1H); 7.12 
(s, 1H); 7.34 (t, J = 8.0 Hz, 1H, H5’); 7.35 (bs, 1H); 7.40 (s, 1H); 9.20 (d, J = 7.6 Hz, 1H, H5).  13C 
NMR (CDCl3, 100 MHz) δ  51.2 (q); 55.5 (q); 104.6 (d); 110.4 (d); 112.4 (d); 114.1 (d); 117.3 (d); 117.8 
(s); 118.4 (s); 119.4 (s); 122.1 (d); 123.0 (d); 123.5 (d); 124.0 (d); 129.6 (d); 130.1 (s); 130.8 (s); 133.4 
(d); 138.9 (s); 145.9 (s); 146.7 (s); 155.2 (s); 155.7 (s); 156.0 (s); 161.8 (s).  MS (MALDI-TOF) 471 (M, 
100).  HRMS m/z calcd. for C27H21NO7  471.1318, found 471.1317.  
Cell growth inhibition assay: screening 
A colorimetric assay using sulforhodamine B (SRB) was adapted to perform quantitative measurement 
of cell growth and viability, following a previously described method.45 Cells were seeded in 96-well 
microtiter plates, at 5 x 103 cells per well, in aliquots of 195 µL of RPMI medium, and were allowed to 
attach to the plate surface by growing in drug-free medium for 18 hours. Afterwards, samples were 
added in aliquots of 5 µL (dissolved in DMSO:H2O, 3:7).  After 72 hours of exposure, the antitumor 
effect was measured by the SRB methodology: cells were fixed by adding 50 µL of cold 50% (wt/vol) 
trichloroacetic acid (TCA) and were incubated for 60 minutes at 4 ºC. Plates were washed with 
deionized H2O and dried; 100 µL of SRB solution (0.4% wt/vol in 1% acetic acid) was added to each 
microtiter well and incubated for 10 minutes at room temperature. Unbound SRB was removed by 
washing with 1% acetic acid. Plates were air-dried and bound stain was solubilized with Tris buffer. 
Optical densities were read on an automated spectrophotometer plate reader at a single wavelength of 
490 nm. Data analyses were generated automatically by LIMS implementation. Using control OD 
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values (C), test OD values (T) and time zero OD values (T0), the drug concentration that causes 50% 
Growth Inhibition (GI50 value) was calculated from the equation: 100 x [(T-T0)/C- T0 )-] = 50. 
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Table 1  
                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 R R2 R3 R4 R5 5 R6 R7 R8 R9 % 
a H H OMe OMe OMe a OiPr H OiPr OMe 80 
b H H H OH H b OiPr H OiPr OiPr 52 
c CMe2CMe2 H OMe OH H c OiPr H OiPr H 64 
d ---- H OMe OiPr H d OiPr OMe OMe H 61 
e H OMe H H OMe e OMe H OiPr OMe 81 
f H H OMe OMe H 9 Scaffold 8 Borolane % 
g H H H OMe H a 8d 4b 76 
h H H OMe H OMe b 8d 4f 89 
i H H H OCF3 H c 8d 4a 71 
j H H H OiPr H d 8d 5a 89 
k H H OiPr H H e 8d 5e Quant. 
l H H H NMe2 H f 8e 5c 82 
m H H NO2 H H g 8e 5b 81 
n H 2-thienyl h 8k 5c 95 
i 8k 5d 93 
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Table 2.  
Cytotoxicity (GI50 µM) Cytotoxicity (GI50 µM) 
Compound 
A-549 HT-29 
MDA-MB- 
231 
Compound 
A-549 HT-29 
MDA-MB- 
231 
Lam-D 0.20 5.1 0.25 
N
CO2Me
MeO
MeO
MeO
HO
HO
OH
OMe
 
15e 8.9 n.a. 7.6 
N
CO2Me
MeO
MeO
iPrO
OMe
MeO
 
6a n.a. n.a. n.a. 
N CO2Me
OH
OMe
MeO
MeO
HO
OH OH
 
15g 13.7 8.4 10.5 
NMeO
iPrO
HO OMe
CO2Me
 
6c 20.3 18.1 19.0 
N CO2Me
OH
MeO
HO
OH
HO
 
15h n.a. n.a. 19.0 
N
CO2Me
iPrO OMe
MeO
iPrO  
6d n.a. n.a. n.a. 
N
CO2Me
OH
MeO
HO
OMe
HO
OMe
 
15i 14.7 n.a. 15.7 
N
CO2Me
Me2N
MeO
iPrO  
6l n.a. n.a. n.a. 
N CO2Me
HO
MeO
OMe
MeO
OMe
 
16a n.a. n.a. n.a. 
N
CO2Me
OMeOMe
OMe
OMeMeO
MeO
MeO
iPrO  
7a 67.9 34.0 n.a. 
N CO2Me
MeO
HO
OMeHO
 
16c 10.9 23.9 11.2 
N
MeO
iPrO
OMe OH
HO MeO
CO2Me
 
7c 14.7 6.9 7.1 
N CO2Me
HO
MeO
MeO
MeO
 
16e 13.3 n.a. 19.9 
N
CO2Me
OMe
OMe
MeO
MeO
MeO
iPrO  
7f 0.81 1.0 0.98 
N CO2Me
HO
MeO
S
 
16n n.a. n.a. 26.3 
N
CO2MeMeO
iPrO
S S
 
7n n.a. n.a. n.a. 
N CO2Me
OMe
MeO
MeO
OMe
MeO
HO
OMe
OMe
 
17a n.a. n.a. n.a. 
N CO2Me
OiPr
iPrO OMe
OMe OiPr
MeO
iPrO  
9d n.a. n.a. n.a. 
N
CO2MeMeO
HO
HO OMe
OMe OH
 
17c 7.1 8.1 7.5 
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N
CO2MeMeO
iPrO
S S
 
11n n.a. n.a. n.a. 
N CO2Me
MeO
HO
MeO OMe
OMe OMe
 
17f n.a. n.a. n.a. 
N CO2Me
OiPr
iPrO OMe
OMe OiPr
MeO
iPrO  
12d n.a. 13.6 n.a. 
N
CO2MeMeO
HO
MeO
OMe
 
17g n.a. 9.7 9.9 
N
CO2MeMeO
HO
OMeHO
 
13c 14.2 18.0 22.3 
N
CO2MeMeO
HO
F3CO
OCF3
 
17i n.a. n.a. n.a. 
N
CO2MeMeO
HO
MeO
OMe
 
13e n.a. n.a. 12.7 
N CO2Me
MeO
HO
OH
HO
 
17j 3.5 9.8 4.1 
N CO2Me
HO
MeO
Me2N
 
13l n.a. n.a. n.a. 
N CO2Me
MeO
HO
HOOH
 
17k 6.3 18.4 7.2 
N
CO2MeMeO
HO
HO OMe
OMe OH
 
14c 14.3 n.a. 8.5 
N
CO2MeMeO
HO
NO2NO2
 
17m n.a. 8.9 18.3 
N CO2Me
MeO
HO
OMeMeO
OMe
OMe
 
14f 11.2 n.a. 7.7 
N CO2Me
HO
MeO
S
S
 
17n 20.4 n.a. 19.7 
N
CO2MeMeO
HO
MeO
OMe
 
14g 9.2 10.3 14.4 
N
HO
MeO
OH
HO OMe
CO2Me
 
18a 9.8 10.1. 15.0 
 
14i n.a. n.a. n.a. 
N
CO2Me
OMe OMeOMeHO
HO
MeO
 
18b n.a. n.a. n.a. 
N CO2Me
MeO
HO
OH
HO
 
14j n.a. n.a. n.a. 
N CO2Me
OH
OHOMeOMeHO
MeO
HO  
18d 0.45 7.9 0.71 
N
CO2MeMeO
HO
Me2N
NMe2
 
14l n.a. n.a. 13.7 
N
CO2Me
MeO
MeO
MeO
HO
HO
OH
OMe
 
18e n.a. n.a. n.a. 
N CO2Me
MeO
HO
NO2 NO2
 
14m 18.0 11.3 10.1 
N
CO2Me
OH
OH OHOMe
MeO
MeO
HO  
18g 4.7 7.1 3.2 
N CO2Me
OH
HO OMe
OMe OH
MeO
HO  
15d 5.0 17.1 3.1 
N CO2Me
MeO
HO
HO
OH
OH
 
18h 20.8 n.a. 10.6 
 
n.a. = not active at 10 µg/mL 
 
N
CO2MeMeO
HO
F3CO
OCF3
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Figure 1.  
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Scheme 1.   
NBS, 
THF
NBS, 
THF
N CO2Me
MeO
iPrO
4, Pd(PPh3)4
K2CO3, DMF
N CO2Me
MeO
iPrO
Br
N CO2Me
MeO
iPrO
Br Br
4, Pd(PPh3)4 
K2CO3, DMF
NBS, 
THF
4 or 5, Pd(PPh3)4 
K2CO3 or K3PO4
DMF
B
R4
R5
OR
OR
R2
R3
B
R8
R9
O
O
R6
R7
N CO2Me
MeO
R1O
R4
R3
R4
R2
R5
R3
R2
R5
N CO2Me
MeO
R1O
R4
R3
R5
R2
DDQ, CHCl3 
MW
N CO2Me
MeO
R1O
R4
R3
R4
R2
R5
R3
R2
R5
N CO2Me
MeO
R1O
R4
R3
R5
R2
N CO2Me
MeO
R1O
R4
R3
R8
R6
R9
R2
R5
R7
N CO2Me
MeO
R1O
R4
R3
R8
R6
R9
R7
R5
R2N CO2Me
MeO
iPrO
R4
R3
Br
R2
R5
1
2
3
7 (R1 = iPr)
14 (R1 = H)
6   (R1 = iPr)
13 (R1 = H)
8
 9   (R1 = iPr)
15  (R1 = H)
12  (R1 = iPr)
18  (R1 = H)
AlCl3, CH2Cl2
AlCl3, CH2Cl2
AlCl3, CH2Cl2 AlCl3, CH2Cl2
11 (R1 = iPr)
17 (R1 = H)
10  (R1 = iPr)
16  (R1 = H)
AlCl3, CH2Cl2
AlCl3, CH2Cl2
4 5
DDQ, CHCl3 
MW
DDQ, CHCl3 
MW
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Scheme Legends 
Table 1.  Substituents of building blocks 4 and 5, and compounds 9   
Table 2. In vitro cytotoxicity of the open-chain analogs of Lam-D and synthetic intermediates 
Figure 1. Structures of lamellarins, camptotecin and scaffold 1 
Figure 2. Minimized energy forms of the two rotamers of compound 12f 
Scheme 1.  Synthesis of open-chain lamellarin analogs library 
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